Salmeterol/fluticasone propionate - Orion

Drug Profile

Salmeterol/fluticasone propionate - Orion

Alternative Names: Easyhaler salmeterol-fluticasone; Fluticasone propionate/salmeterol - Orion

Latest Information Update: 16 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Orion
  • Class Androstadienes; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Phenethylamines; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 07 Aug 2017 Orion plans a phase I trial for Asthma (Healthy volunteers) in Finland (NCT03238482)
  • 21 Dec 2016 Orion Corporation plans to file an MAA with the EMA in 2017
  • 01 Nov 2016 Orion completes a phase I trial in Asthma (In volunteers) in Finland (NCT03060044)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top